Royalty Report: Drugs, Delivery, Cancer – Collection: 298918

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Delivery
  • Cancer
  • Therapeutic
  • Respiratory

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 298918

License Grant
The Company granted Licensee an option to acquire (1) the Company’s rights to an intellectual property portfolio of materials and technology related to narrow spectrum kinase inhibitor compounds (the Licensed Product) and (2) an exclusive, worldwide, royalty bearing license to PUR1800, the Company’s inhaled iSPERSE drug delivery system as formulated with one of the kinase inhibitor compounds. The Company will conduct a clinical and chronic toxicology program beginning in 2020 focused on chronic obstructive pulmonary disease (COPD) and lung cancer interception.
License Property
The Company's product candidates are based on iSPERSEâ„¢, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

'Pulmatrix's iSPERSEâ„¢ platform has the ability to enhance the safety and efficacy profile of promising drug candidates. 'We applied the iSPERSEâ„¢ technology to RV1162/PUR1800, the lead in-licensed inhibitor and helped unlock its clinical potential by improving the product's profile from the original formulation.

Field of Use
These candidates are intended to be developed for lung cancer interception.

Licensee gains an option to access a portfolio of narrow spectrum kinase inhibitors intended for development in lung cancer interception.

IPSCIO Record ID: 213679

License Grant
Licensor hereby grants to English Licensee an exclusive, sub-licensable, license under the Licensor IP to research, have researched, develop, have developed, manufacture, have manufactured, import, register, market, promote, distribute, use, sell, supply and otherwise exploit Products in the Territory; and to otherwise exercise Licensee’s rights and fulfill Licensee’s obligations pursuant to and in accordance with the provisions of this Agreement.

Further, Licensor hereby grants to Licensee a non-exclusive, sub-licensable, licence under the Licensor IP to use the same with clinical comparator products and mono products or combination products solely for the purposes of the development of Products hereunder.

License Property
Licensor Technology means Licensor’s proprietary iSPERSEâ„¢ technology.  iSPERSEâ„¢, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximising local concentrations and reducing systemic side effects to improve patient outcomes.

Licensor IP means
(a)    any and all Intellectual Property owned or controlled by Licensor or its Affiliates at the Effective Date relating to the Licensor Technology and/or Formulation(s), including the Patents and such rights in the Licensor Data; and
(b)    any improvements or developments thereto developed independently of this Agreement; and
(c)    any improvements or developments thereto created or developed by or on behalf of Licensee during the course of this Agreement except to the extent such improvements or developments constitute Licensee IP.

Intellectual Property means patents, supplementary protection certificates, trademarks, service marks, registered designs, rights in designs, applications for any of the foregoing, trade or business names, copyrights, rights under licences and consents for any such thing and all rights or forms of protection of a similar nature or having equivalent or similar effect subsisting anywhere in the world.

Product means any product combining a Device with a Formulation.

Licensor Data means any data, reports or other documentation, including the data package for PUR0200, in Licensor’s possession or under its control as at the Effective Date.

Device means an inhaler device to be determined by Licensee.

Formulation means (a) any formulation of Tiotropium formulated using the Licensor Technology, including PUR0200 and/or (b) any formulation of [*****] formulated using the Licensor Technology.

“[*****]” means [*****] alone for monotherapy, and not in combination with any other active ingredient.

Licensee IP means any Intellectual Property
a)      covering a Device and any formulation of drugs for a Device and owned or controlled by Licensee or its Affiliates as of the Effective Date (which for the avoidance of doubt shall exclude the Formulations and Licensor Technology);
b)      any improvements or developments thereto developed independently of this Agreement;
c)      any improvements or developments thereto created or developed by or on behalf of Licensee during the course of this Agreement; and
d)      created or developed by or on behalf of either Licensee during the course of this Agreement relating to a Device, including without limitation any improvements thereto, and relating to the development, Manufacture and connectivity (for example, but without limitation, mHealth) thereof.

Field of Use
This agreement pertains to the drug industry relating to the field of respiratory disease.

IPSCIO Record ID: 166969

License Grant
Under this agreement, Licensor granted to the exclusive license to manufacture and market Licensors products in the U.S.
License Property
Licensor has a proprietary pulmonary dry powder drug delivery system that is designed to aerosolize pharmaceuticals in dry powder formulations for delivery to the lungs.
Field of Use
Licensee is a specialty respiratory pharmaceutical and pulmonary drug delivery company.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.